Trimer 4571

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIVHIV Infections

Phase 1

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

CompletedNCT04177355

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2020-01-13End: 2024-11-04Updated: 2025-09-02

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

CompletedNCT05781542

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2023-04-10End: 2025-04-14Updated: 2025-11-14

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.

Active, not recruitingNCT06332339

National Institute of Allergy and Infectious Diseases (NIAID)HIV

Start: 2024-03-15End: 2026-11-11Updated: 2024-11-05

Related Papers

Accelerated cGMP production of near-native HIV-1 Env trimers following electroporation transfection and immunogenicity analysis.

2025-08-201 citations